Ricerca Biosciences/Instem Collaboration Delivers Improved Quality in Drug Safety Studies
Ricerca Biosciences
is pleased to announce the successful result of a partnership with
Instem
, a leading provider of laboratory data and information management solutions. The collaboration resulted in the development of a novel approach to eliminating potential misdosing during drug safety studies.
With the goal of improving quality management processes for clients and ensuring the integrity of study data, the Ricerca team in Lyon, France, approached Instem and proposed an upgrade to their
Provantis
software suite, which would help eliminate dosage errors. The Ricerca team created the requirement specifications and Instem enhanced the latest version of Provantis, enabling it to automatically verify and control correct dosing before administration by using existing bar code technology. The enhanced functionality replaces manual controls, which are not completely reliable, and streamlines the drug dosing process, thereby eliminating the potential for errors.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
